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Available online 23 January 2014AbstractBackground: Accelerometers have been suggested to provide additional information during the 6-min walk test which may be useful in eval-
uating changes in functional exercise capacity. The aim of the study was to identify whether the additional information measured by the
MyWellness Key (MWK) accelerometer during a treadmill 6-min walk test (t-6MWT) was related to currently used outcome measures.
Methods: Fifteen participants (9 males, 6 females) performed a self-paced t-6MWT. Respiratory gas analysis and walking distance were
measured whilst wearing the MWK.
Results: A significant correlation was established between activity counts and 6-min walk distance (6MWD) (r¼0.847, p< 0.001) yet not 6-min
walkwork (6MWW) (r¼0.337, p¼ 0.220). Energy expenditure estimated by theMWKwas strongly correlated to 6MWW(r¼ 0.938, p< 0.001)
but not 6MWD (r¼ 0.477, p¼ 0.072). The MWK significantly underestimated energy expenditure (36.73, CI¼ 33.9e39.7 kcal) compared to gas
analysis (54.35, CI¼ 46.2e61.4 kcal) demonstrating poor agreement between the two analyses (Bias¼17.61 kcal, Limits of agreement¼37.4,
þ2.2 kcal). Measurement of time spent undertaking light, moderate, and vigorous physical activity was not significantly different ( p > 0.05)
between the MWK and gas analysis.
Conclusion: Estimated energy expenditure provided by the MWK was strongly correlated to 6MWW; however, MWK underestimated energy
expenditure as measured by gas analysis. The MWK may provide outcome data that supplement those currently provided by the 6MWD for
functional capacity assessment during the t-6MWT.
Copyright  2014, Shanghai University of Sport. Production and hosting by Elsevier B.V. All rights reserved.
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The cardiopulmonary exercise test is a well-established,
non-invasive procedure that is used in the assessment of an
individuals’ tolerance to exercise.1e3 Field tests including the
6-min walk test (6MWT) are commonly used to estimate ex-
ercise capacity,4 whereby a reluctance or inability to perform a* Corresponding author.
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http://dx.doi.org/10.1016/j.jshs.2013.09.005cardiopulmonary exercise test may exist.5 A standardised
treadmill 6MWT (t-6MWT) is an alternative mode of this test
that has been shown to provide constant patient monitoring.6
Where research has indicated that the marker of exercise
intolerance is more closely related to activities of daily living,
such as in chronic obstructive pulmonary disease (COPD), the
6MWT is being frequently used as a measure of functional
capacity.7 Walking tests of this nature are less time consuming
and are being increasingly employed where access to elaborate
equipment may not exist.8 As the test involves a familiar daily
activity, it has been suggested to provide a more valid indi-
cation of the patients’ functional exercise status.9,10 Although
various physiological indices can be measured, outcomeProduction and hosting by Elsevier B.V. All rights reserved.
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been shown to estimate prognosis amongst those with
COPD.11 More recently, 6-min walk work (6MWW), the
product of 6MWD and body mass, has demonstrated an
improved ability to determine resting lung function and pa-
rameters of gas analysis than 6MWD alone in COPD.12
Accelerometry has been proposed as an effective tool in
recording physical activity (PA) patterns within a free living
environment amongst numerous populations13 and is gaining
popularity amongst health care professionals and researchers
alike.14 As objective measuring devices, modern-day accel-
erometers can estimate both energy expenditure (EE) and
exercise intensity during various types of PA using regression
equations.15,16 Recently, accelerometers have been used to
provide alternative outcome measures to assess the functional
capacity of chronic heart failure patients during the 6MWT.17
The MyWellness Key (MWK) (Technogym, Cesena, Italy)
is a new accelerometer which has been shown to be a valid and
reliable method of assessing a variety of PA parameters during
walking and running,18,19 but has not yet been used as a
method of quantifying performance during a functional exer-
cise test. The aim of the study was to identify whether the
MWK could offer additional information during the t-6MWT
that may relate to currently used outcome measures.
2. Methods2.1. Participants and recruitmentFifteen healthy, asymptomatic individuals (Table 1) vol-
unteered to take part in the study (male, n ¼ 9; female, n ¼ 6).
Sample size was estimated using the nroot method.
20 All par-
ticipants gave their written informed consent and were then
screened for inclusion and exclusion criteria. Inclusion criteria
included individuals who were at low-to-moderate risk of
developing cardiovascular disease as identified in accordance
with guidelines proposed by the American College of Sports
Medicine.21 Exclusion within the current study included those
presenting any one of the following criterion: high risk,Table 1
Demographic and spirometric characteristics of participants.
Variable Mean  SD Range
Age (year) 27.13  15.53 18e66
Height (cm) 172.27  8.25 158.80e187.20
Mass (kg) 66.37  9.87 52.92e87.23
BMI (kg/m2) 22.31  2.37 18.31e28.67
Body fat (%) 16.01  11.07 0.90e32.5
FEV1 (L) 3.70  0.88 2.07e5.26
FEV1 (% predicted) 91.61  10.47 81.01e109.98
FVC (L) 4.06  0.84 2.70e5.58
FVC (% predicted) 84.54  9.95 72.39e95.79
FEV1/FVC ratio 90.57  5.93 74.19e96.19
FEV1/FVC (% predicted) 108.26  6.76 91.78e118.11
Abbreviations: BMI ¼ body mass index; FEV1 ¼ forced expiratory volume in
1 s; FVC ¼ forced vital capacity; FEV1/FVC ¼ forced expiratory volume in
1 s, forced vital capacity quotient.smoker, taking any form of regular medication, recent change
in PA status and history of musculoskeletal, respiratory and/or
cardiovascular disease. During screening, resting blood pres-
sure (BP) and heart rate (HRrest) were measured using manual
sphygmomanometry (Dekamet, Accoson, UK). Height and
weight were measured using a stadiometer (Holtain Ltd.,
Crymych, UK). The study was approved by the local ethics
committee of Edge Hill University.2.2. Procedure and measurementsPrior to the t-6MWT, body composition was assessed via
air-displacement plethysmography (Bodpod V.4.2.0; Cosmed,
Rome, Italy) in accordance with the recommendations of
Dempster and Aitkins.22 Assessment of lung function was
carried out at baseline in all participants and was performed
using the single breath technique with a handheld spirometer
(MicroPlus; Carefusion, Basingstoke, UK). Lung function was
determined using the maximum value of three attempts,23 and
compared to predicted pulmonary function.24 Data for body
fat, HRrest, age, sex, height, and body mass were then entered
into the corresponding software (TechnoGym, Cesena, Italy)
of the MWK (Table 1).
Participants mounted the motorised treadmill (Woodway:
ELG, Weil am Rhein, Germany) for the t-6MWT. Pre-test
warm-ups were not permitted, in order to improve intra-
individual consistency and adhere to previously set guide-
lines.24 Continuous breath-by-breath gas analysis (Oxycon
Pro; Jaeger, Carefusion, Ho¨chberg, Germany) was then used to
record respiratory gases prior to and throughout the duration of
the test. Breathing reserve (BR) and _VO2$V
,
could thus be
provided during the t-6MWT, whereby BR represents
the proportion of an individual’s maximal voluntary ventila-
tion that is not utilised during exercise.25 Gas analysis was
averaged 1-min prior to and during each minute of the
t-6MWT. The metabolic equivalent (MET) was calculated
via two methods, as a result of evidence suggesting that
3.5 mL/kg/min does not accurately represent the resting
metabolic rate of a general population26,27 (standardised26
(METs ¼ _VO2=3:5 mL=kg=min) and measured27 (METs ¼
_VO2=pre-test metabolic rate)).
27 Pre-test metabolic rate was
deduced as the mean _VO2 in the minute prior to commencing
the test. The MWK was attached on the right hip, in line with
the midline of the right anterior thigh as recommended by the
manufacturer.18 Participants were then instructed to walk as
far as possible in the allotted time, without jogging or running.
The speed of the treadmill was dictated by the participant,
which was designed to replicate maximal sustainable walking
speed. Participants were instructed to refrain from using the
handrails.28 During the test, participants were verbally
encouraged and the time remaining was indicated every
minute. Encouragement was provided as it has been shown to
significantly increase the distance walked.29 A calm and even
tone was emphasised during phases of encouragement and the
same investigator was used to help minimize variations in the
encouragement offered to participants. The distance was
recorded every minute and at the end of the test. On
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analysed using the manufacturer’s software. Data provided by
the MWK included the total energy expended (MWKEE), time
spent undertaking light, moderate and vigorous PA, and
“moves” collated. The term move represents the volume of
accumulated PA expressed as a simple arbitrary unit, which
derives from a conversion of activity counts using an
algorithm.2.3. Statistical analysisFig. 1. Mean  SEM physiological responses observed during the treadmill
6-min walk test. *Indicates a difference from the previous minute, p < 0.05.
zdenotes a significant difference to all other time point, p < 0.001. yindicates
significantly greater than all but previous minute, p < 0.01.All data were initially tested for normality using a Sha-
piroeWilk test. One-way repeated-measures analysis of vari-
ance was used to identify statistically significant changes in
BR, _VO2 and self-selected treadmill speed during each minute
of the t-6MWT. Post-hoc pairwise comparisons were made
using the Bonferroni confidence interval. Pearson’s correlation
coefficients (r) were used to determine the strength of re-
lationships between currently used outcome measures (6MWD
and 6MWW) and the following variables: demographics
(height, mass, BMI, FEV1, FVC, and FEV1/FVC), parameters
offered by the MWK (EE and moves), and _VO2. Methods for
determining the time spent at light, moderate, and vigorous PA
were analysed using Friedman’s tests, and where significant
differences between assessment methods were observed,
Wilcoxon tests were used to determine the location of specific
differences. Comparisons between MWKEE and gas analysis
EE were made using a paired sample t test and limits of
agreement analysis in accordance with the method of Bland
and Altman.30 Single linear regression analysis was performed
to elucidate the relationship between height and t-6MWT
performance. Significance was set at p < 0.05 and all statis-
tical analysis was conducted using PASW v 18.0 (SPSS IBM,
Armonk, NY, USA), except the limits of agreement analysis
which was conducted using MS Excel 2010 (Microsoft,
London, UK).
3. Results
The self-selected pacing strategy inherent with the t-6MWT
produced significantly different speeds (Fig. 1A) during the
protocol ( f ¼ 12.26, p < 0.001). This was characterised by a
conservatively paced minute 1 which was significantly slower
than any other time during the protocol ( p < 0.05). Speed
between minutes 2 and 4 was unchanged ( p > 0.05), but
increased at minute 5 ( p ¼ 0.004). Whilst there was not a
continued increase to the end of the test, the speed at minute 6
was significantly greater than minutes 1e4 ( p < 0.05). The
_VO2 response (Fig. 1B) was significantly increased during the
protocol ( f ¼ 94.03, p < 0.001) and correlated to the speed
profile (r ¼ 0.779, p < 0.001). Significant increases occurred
at minutes 2 ( p < 0.001), 5 ( p ¼ 0.002), and 6 ( p ¼ 0.030).
Conversely BR (Fig. 1C) significantly declined ( f ¼ 91.14,
p < 0.001) and was negatively correlated with both _VO2
(r ¼ 0.686, p < 0.001) and self-selected walk speed
(r ¼ 0.411, p < 0.001). Decreases were observed each
minute ( p < 0.01) except between minutes 3 and 4 ( p > 0.05).The mean  SD 6MWD and 6MWW achieved during the
t-6MWT was reported at 749.53  94.30 m and
49,714.21  9173.0 kg/m, respectively. For the most part
6MWW was more strongly related to the demographic and
resting pulmonary function variables than 6MWD (Table 2).
Correlation coefficients for _VO2 compared to 6MWD and
Table 2
Pearson’s correlation analysis of 6MWD and 6MWW with demographics and
indices of lung function.
Variable 6MWD 6MWW
r p r p
Height (cm) 0.598 0.019 0.930 0
Mass (kg) 0.430 0.880 0.723 0.002
BMI (kg/m2) 0.588 0.021 0.167 0.551
FEV1 (L) 0.674 0.006 0.763 0.001
FVC (L) 0.620 0.014 0.722 0.002
FEV1/FVC 0.619 0.014 0.578 0.024
Abbreviations: 6MWD ¼ 6-min walk distance; 6MWW ¼ 6-min walk work;
BMI ¼ body mass index; FEV1 ¼ forced expiratory volume in 1 s;
FVC ¼ forced vital capacity; FEV1/FVC ¼ forced expiratory volume in 1 s,
forced vital capacity quotient.
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correlation (r ¼ 0.656, p < 0.001) with minute-to-minute _VO2
(Fig. 2A), but a slightly stronger relationship (Fig. 2B) was
observed between 6MWW and _VO2 (r ¼ 0.703, p < 0.001).
Moves detected by the MWK were compared to 6MWD
(Fig. 3A) and 6MWW (Fig. 3B), and a significant correlation
was established with 6MWD (r ¼ 0.847, p < 0.001) but not
with 6MWW (r ¼ 0.337, p ¼ 0.220). Mean _VO2 showed a
moderate relationship (r ¼ 0.753, p ¼ 0.001) to moves
accrued over the t-6MWT. The MWKEE demonstrated a
notable relationship to 6MWW (r ¼ 0.938, p < 0.001)Fig. 2. The relationship between 6-min walk distance (6MWD), 6-min walk
work (6MWW) and _VO2 ( p < 0.001).(Fig. 3D), but this was not the case between MWKEE and
6MWD (r ¼ 0.477, p ¼ 0.720) (Fig. 3C).
The duration of time spent at different exercise intensities
(Fig. 4) were significantly different between methods of
calculation for moderate (c2 ¼ 15.25, p < 0.001) and vigorous
intensities (c2 ¼ 19.63, p < 0.001), but not light intensity
(c2 ¼ 4.00, p ¼ 0.135). The MWK was not significantly
different to measured ( p > 0.05), but this was not the case for
the standard method, which underestimated time durations at
moderate intensity ( p < 0.01) and over estimated at vigorous
intensity ( p < 0.01). Despite a strong correlation between
MWKEE and gas analysis EE (r ¼ 0.949, p < 0.001), the total
EE was significantly different between the two methods
(t ¼ 6.76, p < 0.001). Mean (CI) MWKEE (36.73 (33.9,
þ39.7) kcal) was considerably lower than that measured via
gas analysis (54.35 (46.2, þ61.4) kcal). Limits of agreement
analysis for EE showed poor agreement (bias ¼ 17.61 kcal,
limits of agreement ¼ 37.4, þ2.2) and the typical error was
reported as 5.12 kcal.
Single linear regression analysis demonstrated that height
was the strongest predictor of t-6MWT performance where
6MWW (r ¼ 0.93, p < 0.001) is the primary outcome mea-
sure. The relationship may be expressed as
y ¼ 1033.7x  128,367; where y is 6MWW (kg$m) and x is
height (cm). The 6MWD also expressed a moderate relation-
ship (r ¼ 0.60, p ¼ 0.019) with participant’s height.
4. Discussion
The aim of the study was to identify whether the MWK
could offer additional information during the t-6MWT that
may relate to currently used outcome measures. This study
provides novel data comparing data from the MWK to gas
analysis and suggests that the MWK has the capacity to offer
additional information during the t-6MWT that is useful in the
assessment of exercise capacity in the absence of gas analysis.
Strong correlations were established between MWKEE and
6MWW as well as between moves and 6MWD. Interestingly
the MWK provided very similar data to that of gas analysis
when categorising time spent at different exercise intensities,
but this was not the case when estimations of EE were
expressed as kcal for MWKEE compared to gas analysis.
Furthermore, the MWK provided lower estimates of EE at
comparable walking speeds to those observed by Bergamin
and colleagues.19 This however is likely to be due to the
present study using a single 6-min bout of exercise rather than
incremental exercise comprising four 5-min stages preceded
by a 10-min warm-up.
The MWK appeared to offer two additional parameters that
relate to either 6MWD or 6MWW (Fig. 3). The negative
relationship observed between moves and 6MWD (Fig. 3A)
may be explained by the observation that as an individual’s
height increases, so too does their 6MWD. As a move repre-
sents a unit that derives from activity counts, it could be
suggested that those with longer limbs accumulate less activity
counts in comparison to their shorter counterparts, thus
reducing the number of moves they attain during the t-6MWT.
Fig. 3. The relationship between parameters offered by the MyWellness Key (MWK) and the treadmill 6-min walk test (t-6MWT). MWKEE ¼ MyWellness
Key energy expenditure; 6MWD ¼ 6-min walk distance; 6MWW ¼ 6-min walk work.
Fig. 4. Mean  SEM measured and predicted time spent at light, moderate,
and vigorous activity. **denotes a significantly different proportion of time
to MWK (MyWellness KeyTM) and measured ( p < 0.001). METs ¼ metabolic
equivalents.
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both 6MWD and 6MWW. Like 6MWD, it could be suggested
that moves is biased towards taller individuals, and should
therefore be used with caution. It is likely that the close
relationship observed between MWKEE and 6MWW may be
due to the fact that both represent a unit of work performed.
Measuring the energy expended during a 6MWT may repre-
sent a more precise way of assessing performance for the same
rationale in using 6MWW rather than 6MWD as proposed by
Carter et al.31 This may be particularly useful when per-
forming tests on level ground. As the MWK significantly
underestimated energy expenditure compared to gas analysis,
the estimation equation may need to be revised.
The 6MWD and 6MWW are both reputable parameters
used in the assessment of functional capacity and prognosis,
and it appears that some of the additional parameters offered
by the MWK could be useful in the evaluation of performance
during the t-6MWT. Employment of the MWK within an
outpatient environment may allow patients to be assessed on a
more routine basis. The application within telemedicine may
permit health professionals to monitor changes in functional
exercise capacity more frequently, helping in the detection of
progression or regression of a patients’ functional status. The
MWK may assist in conducting the test on a more independent
basis, allowing the patient to identify changes in their own
functional status, thus promoting patient independence and
encouraging long term self-management of their condition.
Previous research13 has identified the efficacy of acceler-
ometers in the quantification of PA performed within a free-living environment, yet few have attempted to evaluate
accelerometry in the assessment of performance during clin-
ical exercise testing. In a recent study,32 levels of PA moni-
tored using accelerometry were identified as the most
significant predictor of all-cause mortality amongst patients
with COPD. Likewise, it has been well reported that levels of
daily PA are closely related to the severity of the disease
amongst those with identified COPD.33e36 Moreover, a sig-
nificant and independent relationship has been identified
between daily walking intensity measured using an
MyWellness Key quantification of 6MWT 193accelerometer and health related quality of life.35 These
findings demonstrate that accelerometer derived information
has the ability to determine functional status and well-being
over a duration of time. This finding is consistent with Jehn
et al.17 who have shown that accelerometers can provide a
means of quantifying performance during the 6MWT in
chronic heart failure patients.
In the current study, the majority of variables of measured
resting pulmonary function, specifically FEV1 and FVC, are
better at predicting 6MWW in comparison to 6MWD. These
results suggest that 6MWW represents a more specific
parameter of performance during the t-6MWT than 6MWD.
The indexes of FEV1 and FVC are both related to the capacity
to ventilate and hence perform exercise and activities of daily
living.31 Interestingly, the relationships examined between
6MWW and measured pulmonary function (Table 2) suggest
that the population were subjected to a degree of ventilatory
limitation. Previous research conducted by Carter et al.31
found that 6MWW expressed mild, although statistically sig-
nificant relationships to both FEV1 (r ¼ 0.52, p < 0.001) and
FVC (r ¼ 0.48, p ¼ 0.0001), however poorer correlations were
noted for 6MWD. The results of the present study are
consistent with those of Carter et al.31 and support the finding
that 6MWW is more closely related to pulmonary function as
measured by FEV1 and FVC than 6MWD in both COPD and
healthy individuals.
The _VO2 responses observed during the first 3-min of the
test in the current study are consistent with other studies37,38
examining the physiological responses of the 6MWT in
those with COPD and indicate a “steady-state” status, whereby
a high, yet sustainable level of exercise occurs.38 Steady-state
_VO2 seems to be a distinct feature for both t-6MWT and
corridor 6MWT. Both 6MWD and 6MWW were found to
correlate well to _VO2, highlighting the rationale in employing
the 6MWT as a test of aerobic endurance.39 Calculations of
6MWW were found to create less spread within the data which
is in agreement with previous studies.37,31,40 Minute-to-minute
_VO2 however, has been found to be more strongly correlated
to 6MWD (r ¼ 0.58) and 6MWW (r ¼ 0.81) in those with
COPD as a result of ventilatory restriction limiting their per-
formance.39 This could suggest that whilst 6MWD and
6MWW relate to _VO2 independent of the presence of COPD,
these parameters may be more applicable to a population
restricted by underlying pulmonary pathologies.
5. Conclusion
In addition to 6MWD being used as the primary outcome
measure following a 6MWT, this study represents an initial
assessment of the use of the MWK accelerometer in the pro-
vision of additional data during the t-6MWT. Employment of
the MWK could be useful within an outpatient environment,
whereby MWKEE achieved during the t-6MWT may be used
to assess functional status were access to elaborate equipment
may not exist. The MWK may support the 6MWT in being
adapted as a self-administered assessment tool, thus promoting
patient independence and self-management of their condition.Practitioners should also be aware that when 6MWD is con-
verted into 6MWW, performance during the t-6MWT more
closely reflects aerobic capacity in a healthy population. Ac-
curate estimation of functional exercise capacity with the
MWK within a pulmonary population warrants future research
in a larger cohort of patients.References
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